The motion: Prevention of prostate cancer with a 5α-reductase inhibitor is feasible

European Urology

Volumn 49, Issue 2, 2006, Pages 396-400

  Roehrborn, Claus G ^a,c   Lotan, Y ^c   Tubaro, A ^c   De Nunzio, C ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER MORTALITY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COST OF ILLNESS; GLEASON SCORE; HUMAN; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNITED STATES;

EID: 32044434225     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.013     Document Type: Note

References (0)